A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients

NCT01742676 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Transplantation
Kidney Transplantation
Stable Renal Recipients

Interventions

DRUG: ADVAGRAF
DRUG: PROGRAF

Sponsor

Astellas Pharma Korea, Inc.